Stage I Multiple Myeloma

• Stage I Multiple Myeloma is the earliest and least aggressive form of multiple myeloma, often associated with minimal or no symptoms.
• Diagnosis relies on specific criteria, including low levels of M-protein, minimal bone lesions, and good kidney function, often identified through routine blood tests or imaging.
• Symptoms are often absent or very subtle, making early detection challenging without regular medical check-ups.
• Treatment approaches for Stage I can range from active surveillance (“watch and wait”) to targeted therapies, depending on individual risk factors and disease progression.
• Prognosis for Stage I is generally more favorable compared to later stages, emphasizing the importance of early diagnosis and personalized care.

What is Stage I Multiple Myeloma?

Stage I Multiple Myeloma is the least advanced classification of multiple myeloma, a cancer that originates in plasma cells, a type of white blood cell found in the bone marrow. These cancerous plasma cells multiply uncontrollably, producing abnormal proteins (M-protein) and potentially damaging bones, kidneys, and the immune system. The International Staging System (ISS) and its revised version (R-ISS) are commonly used to classify multiple myeloma into stages, primarily based on levels of albumin, beta-2 microglobulin, lactate dehydrogenase (LDH), and specific chromosomal abnormalities.

In Stage I, the disease is considered to be in its earliest and often least aggressive form. Patients typically have lower levels of M-protein in their blood or urine, normal or near-normal kidney function, and either no or very few bone lesions. This early stage often presents with minimal symptoms, making its detection challenging. According to the American Cancer Society, multiple myeloma is a relatively rare cancer, with an estimated 35,730 new cases diagnosed in the U.S. in 2024, highlighting the importance of understanding its various stages for tailored patient care.

Stage I Multiple Myeloma Symptoms and Diagnosis

Recognizing stage 1 multiple myeloma symptoms can be challenging because they are often subtle or entirely absent. Unlike more advanced stages, patients with Stage I Multiple Myeloma typically do not experience significant bone pain, fatigue, kidney problems, or recurrent infections. When symptoms do occur, they might be non-specific, such as mild fatigue or vague aches, which can easily be attributed to other common conditions.

The process of diagnosing stage 1 multiple myeloma usually involves a combination of tests designed to detect the presence of abnormal plasma cells and assess their impact on the body. These diagnostic tools help confirm the disease and determine its stage. Key diagnostic methods include:

• Blood Tests: Measuring M-protein levels (monoclonal protein), serum free light chains, calcium levels, and kidney function (creatinine).
• Urine Tests: Detecting M-protein (Bence-Jones protein) in a 24-hour urine collection.
• Bone Marrow Biopsy and Aspiration: Examining a sample of bone marrow to determine the percentage of plasma cells and identify any genetic abnormalities.
• Imaging Studies: X-rays, MRI, CT scans, or PET/CT scans to look for bone lesions, which are often minimal or absent in Stage I.

A diagnosis of Stage I typically requires specific criteria, such as beta-2 microglobulin levels less than 3.5 mg/L, serum albumin levels of 3.5 g/dL or greater, and the absence of high-risk chromosomal abnormalities, along with minimal or no evidence of organ damage (CRAB criteria: hypercalcemia, renal failure, anemia, bone lesions).

Stage I Multiple Myeloma Treatment Options

The approach to stage 1 multiple myeloma treatment options is highly individualized and depends on several factors, including the patient’s overall health, specific disease characteristics, and whether symptoms are present. Given that Stage I often presents with minimal or no symptoms and a lower disease burden, active surveillance, also known as “watch and wait,” is a common initial strategy for many patients.

During active surveillance, patients are closely monitored with regular blood tests, urine tests, and imaging to detect any signs of disease progression. This approach aims to delay the start of treatment, thereby avoiding potential side effects of therapy until it is truly necessary. However, for some patients, particularly those with certain high-risk genetic features or signs of progression towards symptomatic disease, active treatment may be considered even at Stage I.

When active treatment is initiated, it may involve a combination of therapies designed to target the cancerous plasma cells. These can include:

• Chemotherapy: Drugs that kill rapidly dividing cells, including cancer cells.
• Targeted Therapy: Medications that specifically target vulnerabilities in cancer cells, such as proteasome inhibitors (e.g., bortezomib) and immunomodulatory drugs (e.g., lenalidomide).
• Immunotherapy: Treatments that boost the body’s own immune system to fight cancer, including monoclonal antibodies (e.g., daratumumab).
• Corticosteroids: Drugs like dexamethasone, often used in combination with other therapies to kill myeloma cells and reduce inflammation.

Stem cell transplantation, while a potent treatment, is generally reserved for more advanced stages or for patients whose disease progresses despite initial therapies. The choice of treatment is always a shared decision between the patient and their healthcare team, weighing the benefits against the potential risks and side effects of each option.